

REDX PHARMA PLC
("Redx" or "the Company" or "Redx Pharma")

Notice of Annual General Meeting and guidance for shareholders

Alderley Park, 5 February 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that its Annual General Meeting will be held at 11am on 2 March 2021 at Block 33, Mereside, Alderley Park, Macclesfield SK10 4TG.

Following the announcement of preliminary results for the financial year ended 30 September 2020 on 27 January, the Company announces that the Annual Report and Accounts and notice of Annual General Meeting have now been posted to shareholders. The Annual Report and Accounts is also available to view on Redx's website at www.redxpharma.com.

In light of the Stay-at-Home Measures which prohibit all non-essential travel and larger public gatherings and to ensure the safety of the limited number of people whose attendance at the meeting is essential, shareholders will not be allowed into the Annual General Meeting.

At previous Annual General Meetings, once the formal business of the Meeting has been completed, management have taken the opportunity to provide a business update presentation to those shareholders who attend the meeting in person. This year, given measures associated with the COVID-19 pandemic, such a presentation will not be provided and the Meeting shall focus entirely upon conducting the formal business of the Meeting. However, the Company values engagement with its shareholders and, accordingly, shareholders may submit questions related to the business of the AGM to the directors in advance of the Meeting. Questions should be submitted by 5:30 p.m. on 25 February 2021 and addressed to Andrew Booth, Company Secretary, by email at a.booth@redxpharma.com.

Following the AGM, the Board will respond to any questions submitted by shareholders in advance of the meeting and the answers will be posted on the investor FAQs section of the Company website.

Shareholders are strongly encouraged to vote by proxy, appointing the Chairman of the meeting, using the card distributed with the notice of meeting, to ensure their vote counts. The proxy is also available in the investor resources section of the Company's website: www.redxpharma.com

Completed proxies should be returned to:

Equiniti
Aspect House
Spencer Road
Lancing
BN99 6DA

and must be received by 11am on 26 February 2021 to be valid.

The COVID-19 situation continues to evolve, and further announcements regarding the Annual General Meeting may be required in due course. The Company will seek to ensure that shareholders remain fully informed at all times.

For further information, please contact:

Redx Pharma Plc **T: +44 1625 469 918**

Iain Ross, Chairman
Lisa Anson, Chief Executive Officer
James Mead, Chief Financial Officer

SPARK Advisory Partners (Nominated Adviser) **T: +44 203 368 3550**

Matt Davis/Adam Dawes

WG Partners LLP (Broker) **T: +44 20 3705 9330**

Claes Spång/Chris Lee/David Wilson

FTI Consulting **T: +44 20 3727 1000**

Simon Conway/Ciara Martin

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical Proof of Concept. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a Phase 1 clinical study in H1 2021.

The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAUPUPPPUPGGMA